We are live on ! Find out more
LC

Lindbrook Capital Portfolio holdings

AUM $1.08B
1-Year Est. Return 10.14%
This Fund
S&P 500
This Quarter Est. Return
-5.02%
1 Year Est. Return
+10.14%
3 Year Est. Return
+35.77%
5 Year Est. Return
+141.26%
10 Year Est. Return
AUM
$593M
AUM Growth
-$12M
Cap. Flow
+$24.6M
Cap. Flow %
4.16%
Top 10 Hldgs %
49.61%
Holding
3,046
New
350
Increased
1,337
Reduced
784
Closed
167

Sector Composition

Rank Sector Weight
1 Financials 19.66%
2 Technology 11.68%
3 Healthcare 5.39%
4 Consumer Discretionary 4.17%
5 Energy 3.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WYNN icon
1701
Wynn Resorts
WYNN
$10.6B
$5K ﹤0.01%
79
-10
-11% -$623
XLRE icon
1702
State Street Real Estate Select Sector SPDR ETF
XLRE
$8.54B
$5K ﹤0.01%
139
YEXT icon
1703
Yext
YEXT
$577M
$5K ﹤0.01%
1,067
+425
+66% +$1.97K
HTB
1704
HomeTrust Bancshares
HTB
$826M
$5K ﹤0.01%
218
+200
+1,111% +$4.83K
RVNC
1705
DELISTED
Revance Therapeutics, Inc.
RVNC
$5K ﹤0.01%
191
+30
+19% +$609
NWLI
1706
DELISTED
National Western Life Group, Inc. Class A
NWLI
$5K ﹤0.01%
29
+20
+222% +$3.89K
TARO
1707
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$5K ﹤0.01%
181
+117
+183% +$4.03K
SLACU
1708
DELISTED
Social Leverage Acquisition Corp I Units, each consisting of one share of Class A common stock and one-fourth of one redeemable warrant
SLACU
$5K ﹤0.01%
550
UTAAU
1709
DELISTED
UTA Acquisition Corporation Units
UTAAU
$5K ﹤0.01%
500
TCRR
1710
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$5K ﹤0.01%
3,050
AQUA
1711
DELISTED
Evoqua Water Technologies Corp. Common Stock
AQUA
$5K ﹤0.01%
150
+113
+305% +$4.1K
ATCO
1712
DELISTED
Atlas Corp.
ATCO
$5K ﹤0.01%
334
OPNT
1713
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$5K ﹤0.01%
500
HSKA
1714
DELISTED
Heska Corp
HSKA
$5K ﹤0.01%
68
+42
+162% +$3.71K
SLY
1715
DELISTED
SPDR S&P 600 Small Cap ETF (based on S&P SmallCap 600 Index--symbol SML)
SLY
$5K ﹤0.01%
67
ABR icon
1716
Arbor Realty Trust
ABR
$1,000M
$4K ﹤0.01%
390
ACM icon
1717
Aecom
ACM
$9.42B
$4K ﹤0.01%
52
-10
-16% -$709
ACRS icon
1718
Aclaris Therapeutics
ACRS
$867M
$4K ﹤0.01%
239
+31
+15% +$488
ADV icon
1719
Advantage Solutions
ADV
$383M
$4K ﹤0.01%
+81
New +$7.47K
ALDX icon
1720
Aldeyra Therapeutics
ALDX
$91.1M
$4K ﹤0.01%
761
ALX
1721
Alexander's
ALX
$1.38B
$4K ﹤0.01%
21
+19
+950% +$4.49K
AMCR icon
1722
Amcor
AMCR
$21.8B
$4K ﹤0.01%
81
-172
-68% -$10.5K
AMKR icon
1723
Amkor Technology
AMKR
$13.1B
$4K ﹤0.01%
213
-62
-23% -$1.19K
AMPH icon
1724
Amphastar Pharmaceuticals
AMPH
$896M
$4K ﹤0.01%
144
+68
+89% +$2.22K
ANIP icon
1725
ANI Pharmaceuticals
ANIP
$1.72B
$4K ﹤0.01%
125

Similar funds

Lindbrook Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Lindbrook Capital held 3,046 positions worth $593M, down 2% from $605M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Lindbrook Capital deployed $24.6M of net new capital in Q3 2022, opening 350 new positions and adding to 1,337 existing holdings. Its largest new stake was Berkshire Hathaway Class A: 1 share worth $406K.

By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 19% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was iShares MSCI EAFE ETF, an estimated $1.03M trimmed.

  • Lindbrook Capital's largest Q3 2022 buy was Berkshire Hathaway Class A: 1 share worth $406K.
  • Lindbrook Capital added most to RPAR Risk Parity ETF in Q3 2022, an estimated $5.24M increase.
  • Lindbrook Capital's biggest Q3 2022 reduction was iShares MSCI EAFE ETF, cutting an estimated $1.03M.
  • Lindbrook Capital fully exited ProShares UltraShort S&P500 in Q3 2022, selling an estimated $219K.
  • Lindbrook Capital's ten largest holdings make up 50% of its $593M portfolio in Q3 2022.
  • Lindbrook Capital opened 350 new positions and closed 167 in Q3 2022.
  • Lindbrook Capital's portfolio value fell 2% quarter-over-quarter to $593M.

Based on Lindbrook Capital's 13F filing for Q3 2022, filed 10 Nov 2022.